The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA highlighted commercial insurer operating methods and prescription drug costs as cost drivers incurred by hospitals and health systems. AHA urged Congress for additional oversight of Medicare Advantage plans to stop tactics that restrict and delay care access and called for regulatory and legislative solutions to improve prior authorization processes. Recent legislative efforts to no longer recognize price estimator tools as a method to meet the shoppable services requirement of the Hospital Price Transparency Rule are also a concern, AHA said. As Congress looks at statutory adjustments to the rule, AHA urged consideration of the changes that the Centers for Medicare & Medicaid Services makes on a regular basis. The most recent changes are related to standardization, new data elements, file accessibility, an accuracy and completeness affirmation and changes to CMS’ monitoring and enforcement processes.

Related News Articles

Headline
The Senate Special Committee on Aging held a hearing Feb. 11 on issues impacting physician burnout. The AHA provided a statement for the hearing and urged…
Headline
The Centers for Medicare & Medicaid Services has released a new link for its webinar on Feb. 11 at 2 p.m. ET on updated hospital price transparency…
Perspective
Public
More than 34.1 million Americans were enrolled in a Medicare Advantage plan in 2025, accounting for 54% of all Medicare beneficiaries. We have seen enrollment…
Headline
A KFF survey published today found that people view prior authorization as the biggest challenge beyond costs when navigating the health care system. In terms…
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…